[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100533666":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":20,"responsibleParty":30,"collaborators":20,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":37,"acronym":20,"eligibilityCriteria":38,"healthyVolunteers":35,"sex":39,"minAge":40,"maxAge":41,"enrollmentInfo":42,"targetDuration":20,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":20,"overallStatus":51,"whyStopped":20,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":20},{"fullName":5,"class":6},"Tianjin Medical University General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Hematopoietic Stem Cell Transplantation","EXPERIMENTAL","Patients will undergo stem cell transplantation for the treatment of refractory MS",[13],"Procedure: Autologous haemopoietic stem cell transplantation",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","Autologous haemopoietic stem cell transplantation","Immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT).\n\nStem cell mobilization with cyclophosphamide 2g\u002Fm2 and filgrastim 10 ug\u002Fkg\u002Fd x 5 day.\n\nStem cell collection with cobe cpectra stem cell purification with Miltenyi CliniMACS Stem cell transplant conditioning with busulphan 3.2 mg\u002Fkg ; fludarabine 30mg\u002Fm2 or cladribine 10mg ；cytarabine 1-2g\u002Fm2 or idarubicin 8mg\u002Fm2；cyclophosphamide 40mg\u002Fkg followed by CD34 selected autologous hematopoietic stem cell transplant.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Qiang Liu, M.D.,Ph.D","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","+86 15022439149","qliu@tmu.edu.cn",{"type":24,"investigatorFullName":31,"investigatorTitle":32,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Qiang Liu","Professor of Department of Neurology","100533666","autologous-hematopoietic-stem-cell-transplantation-for-refractory-multiple-sclerosis-100533666",false,"NCT06228781","Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis","Inclusion Criteria:\n\n1. Age 18-60 years;\n2. Diagnosed multiple sclerosis with relapses or progression and sustained accumulated impairment by a neurologist expert in the field;\n3. EDSS score of 3-6 (including 3 and 6);\n4. EDSS cerebellar functional score ≥ 3 or EDSS pyramidal functional score ≥3；\n5. Evidence of current disease activity;\n6. If a patient has previously received a cytotoxic agent (mitoxantrone, cyclophosphamide etc.) they must have normal bone marrow morphology and cytogenetics before being considered eligible for this study ;\n7. No evidence of hepatic inflammation or fibrosis;\n\nExclusion Criteria:\n\n1. Patients with evidence of myelodysplasia or other non-autoimmune cytopenia;\n2. Patients having received a cytotoxic agent within one month of enrolling in this study;\n3. Patient with any active or chronic infection (herpes simplex virus, varicella-zoster virus, cytomegalovirus, EB virus, human immunodeficiency virus, hepatitis virus, syphilis, etc.);\n4. Patients having received a cytotoxic agent within one month of enrolling in this study;\n5. Patients with a malignant tumor currently or within the last 5 years;\n6. Patients with cardiac, renal, pulmonary, hepatic or other organ impairment;\n7. Patients whose life expectancy is severely limited by another conditions;\n8. Pregnancy or risk of pregnancy;\n9. Patients unable to give written informed consent in accordance with research ethics board guidelines.","ALL","18 Years","60 Years",{"count":43,"type":44},20,"ESTIMATED","INTERVENTIONAL",[47],"NA","Autologous hematopoietic stem cell transplantation (aHSCT) is the only treatment for refractory autoimmune diseases capable of inducing long-term, drug-free and asymptomatic remission. Over the past two decades, aHSCT has been used to treat inflammatory autoimmune disease of the CNS. Patients with relapsing-remitting multiple sclerosis benefit from aHSCT treatment. However, a certain percentage of patients still experience recurrence 3 or 5 years after transplantation. Therefore, exploration of conditioning regimens will drive therapeutic advances in aHSCT in autoimmune diseases of the CNS.",[50],"Multiple Sclerosis","NOT_YET_RECRUITING","2025-05-25",{"date":54,"type":55},"2025-05-30","ACTUAL",{"date":57,"type":44},"2026-12-01",{"date":59,"type":44},"2029-01-01",{"name":5,"class":6}]